| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
20,018 |
17,537 |
$1.20M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,464 |
12,078 |
$532K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14,213 |
13,047 |
$329K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,291 |
3,105 |
$238K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,263 |
3,127 |
$218K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,500 |
3,042 |
$203K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,045 |
2,850 |
$200K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
11,254 |
10,338 |
$150K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,211 |
2,041 |
$144K |
| 87428 |
|
4,133 |
3,070 |
$104K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
6,502 |
6,085 |
$83K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
639 |
480 |
$52K |
| 87430 |
|
4,165 |
3,593 |
$39K |
| 92551 |
|
2,911 |
2,767 |
$23K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
712 |
450 |
$22K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,845 |
1,574 |
$15K |
| 87634 |
|
262 |
196 |
$11K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,870 |
1,667 |
$11K |
| 99188 |
|
528 |
443 |
$9K |
| 99215 |
Prolong outpt/office vis |
93 |
89 |
$9K |
| 99050 |
|
635 |
520 |
$8K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
344 |
208 |
$8K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
91 |
90 |
$6K |
| 99499 |
|
586 |
550 |
$6K |
| 90474 |
|
661 |
608 |
$5K |
| 99173 |
|
2,985 |
2,823 |
$5K |
| 99051 |
|
276 |
271 |
$4K |
| 87807 |
|
272 |
248 |
$3K |
| 90621 |
|
550 |
475 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
70 |
48 |
$2K |
| 90651 |
|
978 |
899 |
$2K |
| 99381 |
|
13 |
13 |
$988.44 |
| 83655 |
|
119 |
67 |
$598.87 |
| 90473 |
|
55 |
54 |
$469.35 |
| 90686 |
|
1,262 |
1,136 |
$352.91 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
28 |
28 |
$330.82 |
| 90619 |
|
257 |
248 |
$295.92 |
| 81002 |
|
149 |
130 |
$262.35 |
| 90674 |
|
146 |
143 |
$209.58 |
| 96380 |
|
16 |
15 |
$185.27 |
| 90715 |
|
156 |
153 |
$176.98 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
15 |
$148.14 |
| 85018 |
|
78 |
76 |
$145.88 |
| 90734 |
|
597 |
530 |
$116.39 |
| 90672 |
|
179 |
170 |
$86.88 |
| 96160 |
|
43 |
40 |
$18.75 |
| 90633 |
|
1,292 |
1,207 |
$0.10 |
| 90381 |
|
12 |
12 |
$0.01 |
| 90671 |
|
285 |
213 |
$0.01 |
| 90698 |
|
961 |
916 |
$0.00 |
| 90680 |
|
588 |
548 |
$0.00 |
| 90744 |
|
235 |
220 |
$0.00 |
| 90697 |
|
164 |
138 |
$0.00 |
| 90696 |
|
16 |
15 |
$0.00 |
| 90670 |
|
1,517 |
1,429 |
$0.00 |
| 90710 |
|
27 |
26 |
$0.00 |
| 90685 |
|
133 |
131 |
$0.00 |
| 90661 |
|
17 |
16 |
$0.00 |